Akari Therapeutics

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Boston, MA.

NEW YORK and LONDON, Aug.  30, 2019  (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA).

Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA)

- Positive early safety and efficacy data with nomacopan

Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress

Some recent biopharma news concerning Akari Therapeutics getting Fast Track approval from the FDA has AKTX stock flying high on Wednesday.
The post Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today appeared first on InvestorPlace.

Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today

The thinly traded, nano-cap biotech Akari Therapeutics PLC (NASDAQ: AKTX) gap-opened higher Wednesday morning, and shares were advancing strongly on above-average volume.

Why Shares Of Micro-Cap Biotech Akari Therapeutics Are Ripping Higher

Akari Therapeutics PLC (NASDAQ: AKTX) shares jumped on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its stem cell transplant treatment.

Good News for Stem Cell Transplants

Shares of Akari Therapeutics PLC rocketed 61% to pace all premarket gainers in very active trading Wednesday, after the biopharmaceutical company said its treatment (nomacopan) of stem-cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients was granted "Fast Track" designation by the U.S.

Akari Therapeutics' stock rockets on heavy volume after FDA grants nomacopan 'Fast Track' designation

Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.

Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study

Shares of Akari Therapeutics PLC (NASDAQ: AKTX)  were soaring Wednesday.

Akari's Lead Candidate Found Safe, Effective In Treating Eye Inflammation

Akari announced positive results from its phase 2 study using Coversin to treat patients with bullous pemphigoid.

Akari Makes Its Mark In Phase 2 Study Against Rare Disease

Akari Therapeutics PLC (NASDAQ: AKTX) shares were surging Tuesday, breaking above the $4 barrier for the first time in about a month.

Microcap Biotech Akari Rallies On Coversin Trial Results

Akari Therapeutics PLC shares were surging by more than 150 percent Wednesday after reporting a positive meeting with the FDA.

Why Thinly Traded Biotech Akari Is Jumping More Than 150%

Shares of Akari Therapeutics PLC more than doubled--soaring 145%--toward a 15-month high in very active morning trade Wednesday.

Akari Therapeutics' stock rockets on massive volume after 'successful' pre-IND FDA meeting

News for Akari Therapeutics Stock (AKTX)